Chemokine Continues Phase I/II Cancer Trial
Posted on: Tuesday, 11 December 2007, 15:00 CST
Chemokine Therapeutics has reported that the company is continuing to treat patients with stable disease participating in the CTCE-9908 Phase I/II clinical trial.
Although enrollment was completed at the end of September 2007, three patients with stable disease continue to receive CTCE-9908 therapy. One patient with small bowel carcinoma is now completing the seventh month of therapy, the maximum allowed by the protocol.
Ongoing results of the Phase I/II trial continue to demonstrate that CTCE-9908 is well tolerated with no dose limiting toxicity observed up to the maximum dose of 5mg/kg/day that was tested. The main side effect at the maximum dose tested has been moderate phlebitis (blood vessel inflammation).
The patients enrolled in this study all had terminal cancers with metastatic disease that no longer responded to standard therapy, or for which no curative therapy exists. The company is continuing with its plans to start an international Phase II study in 2008 and is currently seeking to secure funding.
Walter Korz, vice president, drug development at Chemokine, said: "The Phase I/II trial appears to have demonstrated that CTCE-9908 can be delivered for an extended period of time with limited toxicities."
Source: Datamonitor
Related Articles
- TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
- Penwest Initiates Dosing in Phase Ia Mitochondrial Disease Trial
- Pacgen Announces Positive Results From Phase IIb Dose-Ranging Trial of PAC-113
- Pacgen Completes Patient Recruitment for Phase II Dose Ranging Trial of Novel Anti-Fungal Drug
- TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated With Schizophrenia
- TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
- Patient Enrollment on Target in National Institutes of Health Phase III Parkinson's Disease Trial
- Opexa Therapeutics Reports Positive Top-Line Data in Phase I/II Dose Escalation Trial With Tovaxin(TM) for Multiple Sclerosis
- Vista Partners Updates Coverage on Avicena Group to Address Company's Recently Announced National Institute of Neurological Disorders Funded Phase III Parkinson's Disease Trial
- Avicena Announces Patient Enrollment in National Institutes of Health (NIH) Phase III Parkinson's Disease Trial
 |
 |
User Comments (0)
RSS Feeds